REGLAN ODT Drug Patent Profile
✉ Email this page to a colleague
When do Reglan Odt patents expire, and what generic alternatives are available?
Reglan Odt is a drug marketed by Meda Pharms and is included in one NDA.
The generic ingredient in REGLAN ODT is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Reglan Odt
A generic version of REGLAN ODT was approved as metoclopramide hydrochloride by TEVA on July 29th, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REGLAN ODT?
- What are the global sales for REGLAN ODT?
- What is Average Wholesale Price for REGLAN ODT?
Summary for REGLAN ODT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 34 |
| Patent Applications: | 105 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for REGLAN ODT |
| DailyMed Link: | REGLAN ODT at DailyMed |
Recent Clinical Trials for REGLAN ODT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mercy Health System | Phase 4 |
| Women and Infants Hospital of Rhode Island | Phase 2 |
| Emory University | Phase 4 |
US Patents and Regulatory Information for REGLAN ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-001 | Jun 10, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-002 | Jun 10, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REGLAN ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-001 | Jun 10, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-002 | Jun 10, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-002 | Jun 10, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Meda Pharms | REGLAN ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021793-001 | Jun 10, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for REGLAN ODT
See the table below for patents covering REGLAN ODT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2001524956 | ⤷ Sign Up | |
| Denmark | 2266538 | ⤷ Sign Up | |
| Australia | 726336 | ⤷ Sign Up | |
| Hong Kong | 1137654 | ⤷ Sign Up | |
| Canada | 2284663 | DISSOLUTION RAPIDE DE FORME POSOLOGIQUE DE BONNE TENUE (RAPIDLY DISSOLVING ROBUST DOSAGE FORM) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
